Некоторые аспекты патогенеза анкилозирующего спондилита
- Авторы: Эрдес Ш.1, Erdes S.2
-
Учреждения:
- Научно-исследовательский институт ревматологии РАМН
- Research Institute of Rheumatology of the Academy of Medical Sciences, Moscow
- Выпуск: Том 83, № 5 (2011)
- Страницы: 51-56
- Раздел: Передовая статья
- URL: https://journals.rcsi.science/0040-3660/article/view/30856
- ID: 30856
Цитировать
Полный текст
Аннотация
Анкилозирующий спондилит (АС) - хроническое воспалительное ревматическое заболевание позвоночника (спондилит) и крестцово-подвздошных суставов (сакроилеит), нередко сочетающееся с воспалительными поражениями периферических суставов (артрит), энтезисов (энтезит), а также в ряде случаев - глаз (увеит), кишечника (энтерит) и корня аорты (аортит). В настоящее время АС рассматривают в качестве прототипа заболеваний, входящих в группу серонегативных спондилоартритов.
АС - наследственное заболевание, предрасположенность к которому практически на 90% определяется генетическими факторами, в качестве ключевого гена этой предрасположенности рассматривается HLA-B27. В связи с тем что до сих пор не существует единой общепризнанной теории патогенеза АС, рассмотрены 3 гипотезы, в основе которых лежат данные о биологии HLA-B27. Обсуждаются также возможные внешнесредовые факторы, участвующие в развитии АС, - напряжение в энтезах и инфекции.
АС - наследственное заболевание, предрасположенность к которому практически на 90% определяется генетическими факторами, в качестве ключевого гена этой предрасположенности рассматривается HLA-B27. В связи с тем что до сих пор не существует единой общепризнанной теории патогенеза АС, рассмотрены 3 гипотезы, в основе которых лежат данные о биологии HLA-B27. Обсуждаются также возможные внешнесредовые факторы, участвующие в развитии АС, - напряжение в энтезах и инфекции.
Ключевые слова
Об авторах
Шандор Эрдес
Научно-исследовательский институт ревматологии РАМН
Email: erdes@irramn.ru
д-р мед. наук, проф., зам. дир. по научной работе, зав. лаб. серонегативных спондилоартритов, тел.: 8-499-614-44-86; Научно-исследовательский институт ревматологии РАМН
Sh Erdes
Research Institute of Rheumatology of the Academy of Medical Sciences, MoscowResearch Institute of Rheumatology of the Academy of Medical Sciences, Moscow
Список литературы
- Sieper J., Rudwaleit M., Khan M. A., Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract. Res. Clin. Rheumatol. 2006; 20: 401-417.
- Беленький А. Г. Энтезопатии при серонегативных спондилоартритах. Consilium Medicum 2006; 8: 12-16.
- Goh L., Samanta A. A systematic MeDLiNe analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol. Int. 2009; 29: 1123-1135.
- McLeod C. et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Hlth Technol. Assess. 2007; 11: 1- 158, iii-iv.
- Zochling J. et al. ASAS/eULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 2006; 65: 442-452.
- Schett G., Landewé R., van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann. Rheum. Dis. 2007; 66: 709-711.
- van der Heijde D. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthr. and Rheum. 2008; 58: 3063-3070.
- van der Heijde D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthr. and Rheum. 2008; 58: 1324-1331.
- van der Heijde D., Salonen D., Weissman B. N. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthr. Res. Ther. 2009; 11: R127.
- Cawley M. I., Chalmers T. M., Kellgren J. H., Ball J. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann. Rheum. Dis. 1972; 31: 345-358.
- Appel H. et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthr. and Rheum. 2006; 54: 2845-2851.
- Appel H. et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthr. and Rheum. 2006; 54: 1805-1813.
- Francois R. J., Neure L., Sieper J., Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann. Rheum. Dis. 2006; 65: 713-720.
- Maksymowych W. P., Chiowchanwisawakit P., Clare T. et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndes mophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthr. and Rheum. 2009; 60: 93-102.
- McGonagle D., Wakefied R. J., Tan A. L. et al. District topography of erosion and new bone formation in Achilles tendon enthesits: Implications for understanding the link between inflammation and bone formation in spondyloarthritis. Arthr. and Rheum. 2008; 58; 2964-2969.
- Benjamin M., McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J. Anat. 2001; 199; 503-506.
- Benjamin M., McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv. Exp. Med. Biol. 2009; 649: 57-70.
- Brown M. A. et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthr. and Rheum. 1997; 40: 1823-1828.
- Brown M. A., Laval S. H., Brophy S., Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann. Rheum. Dis. 2000; 59: 883-886.
- Burton P. R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 2007; 39: 1329-1337.
- Australo-Anglo-American Spondyloarthritis consortium (TASC); Reveille J. D. et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat. Genet. 2010; 42: 123-127.
- Choi C., Kim T., Jun J. et al. ARTS1 polymorphisms are associated with ankylosing spondylitis in Koreans. Ann. Rheum. Dis. 2010; 69: 582-584.
- Cui X., Rouhani F. N., Hawari F., Levine S. J. An aminopeptidase, ARTS-1, is required for inter1eukin-6 receptor shedding. J. Biol. Chem. 2003; 278: 28677-28685.
- Thomas G. P., Brown M. A. Genetics and genomics of ankylosing spondylitis. Immunol. Rev. 2010; 233: 162-180.
- Layh-Schmitt G., Colbert R. A. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr. Opin. Rheumatol. 2008; 20: 392-397.
- van den Berg W. B., Miossec P. iL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009; 5: 549-553.
- Genovese M. C. et al. LY2439821, a humanized anti-iL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthr. and Rheum. 2010; 62: 929-939.
- Palodini F., Belfiore F., Cocco E. et al. HLA-E gene polymorphism associates with ankylosing spondylitis. Arthr. Res. Ther. 2009; 11: R171 (doi:10.1186ar 2860).
- Lopez-Larrea C., Blanko-Gelaz M. A., Torre-Alonzo J. C. Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian population. Arthr. Res. Ther. 2006; 8: R101 (doi 10.1186a/ar1988).
- Khan M. A. Epidemiology of HLA-B27 and arthritis. Clin. Rheumatol. 1996; 15 (Suppl. 1): 10-12.
- Hammer R. E., Maika S. D., Richardson J. A. et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63; 1099-1112.
- Milia A. F. et al. HLA-B27 transgenic rat: an animal model mimicking gut and joint involvement in human spondyloarthritides. Ann. N. Y. Acad. Sci. 2009; 1173: 570-574.
- Taurog J. D. et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol. Rev. 1999; 169: 209-223.
- Brown M. A. Genetics and the pathogenesis of ankylosing spondylitis. Curr. Opin. Rheumatol. 2009; 21: 318-323.
- Reveille J. D. Recent studies on the genetic basis of ankylosing spondylitis. Curr. Rheumatol. Rep. 2009; 11: 340-348.
- Reveille J. D., Maganti R. M. Subtypes of HLA-B27: history and implications in the pathogenesis of ankylosing spondylitis. Adv. Exp. Med. Biol. 2009; 649: 159-176.
- Brewerton D. A. et al. Ankylosing spondylitis and HL-A 27. Lancet 1973; 1: 904-907.
- Schlosstein L., Terasaki P. I., Bluestone R., Pearson C. M. High association of an HL-A antigen, W27, with ankylosing spondylitis. N. Engl. J. Med. 1973; 288: 704-706.
- Feldmann M., Maini S. R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev. 2008; 223: 7-19.
- Redlich K., Gortz B., Hayer S. et al. Overexpression of tumor necrosing factor causes bilateral sacroiliitis. Arthr. and Rheum. 2004; 50: 1001-1005.
- Tracey D., Klareskog L., Sasso E. H. et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008; 117: 244-279.
- Gorga J. C., Madden D. R., Prendergast J. K. et al. Crystallization and preliminary X-ray diffraction studies of the human major histocompatibility antigen HLA-B27. Proteins 1992; 12: 87-90.
- Madden D. R., Gorga J. C., Strominger J. L., Wiley D. C. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992; 70: 1035-1048.
- Van Kaer L. Major histocompatibility complex class i-restricted antigen processing and presentation. Tissue Antigens 2002; 60: 1-9.
- Zhao L., Fong Y., Granfors K. et al. Identification of cytokines that might enhance the promoter activity of HLA-B27. J. Rheumatol. 2008; 35: 862-886.
- Kanaseki T., Blanchard N., Hammer G. E. et al. eRAAP synergizes with MHC class i molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity 2006; 25: 795-806.
- Yan J. et al. In vivo role of eR-associated peptidase activity in tailoring peptides for presentation by MHC class ia and class ib molecules. J. Exp. Med. 2006; 203: 647-659.
- Turner M. J., Delay M. L., Bai S. et al. HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthr. and Rheum. 2007; 56: 215-223.
- Colbert R. A., Delay M. L., Layh-Schmitt G., Sowders D. P. HLA-B27 misfolding and spondyloarthropathies. Prion 2009; 3: 15-26.
- Smith J. A. et al. Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic iFN-beta induction via X-box binding protein 1. Eur. J. Immunol. 2008; 38: 1194-1203.
- Dong W. et al. Upregulation of 78-kDa glucoseregulated protein in macrophages in peripheral joints of active ankylosing spondylitis. Scand. J. Rheumatol. 2008; 37: 427-434.
- Gu J. et al. Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J. Rheumatol. 2002; 29: 2159-2164.
- Young A. C., Zhang W., Sacchettini J. C., Nathenson S. G. MHC class i - peptide interactions and TCR recognition. Cancer Surv. 1995; 22: 17-36.
- López de Castro J. A. HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol. Lett. 2007; 108: 27-33.
- Atagunduz P. et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthr. and Rheum. 2005; 52: 892-901.
- Fiorillo M. T., Maragno M., Butler R. et al. CD8(+) T-cell autoreactivity to an HLA-B27-restricted selfepitope correlates with ankylosing spondylitis. J. Clin. Invest. 2000; 106: 47-53.
- Zou J., Appel H., Rudwaleit M. et al. Analysls of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann. Rheum. Dis. 2005; 64: 722-729.
- Kollnberger S., Bowness P. The role of B27 heavy chain dimer immune receptor interactions in spondyloarthritis. Adv. Exp. Med. Biol. 2009; 649: 277-285.
- Kollnberger S. et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthr. and Rheum. 2002; 46: 2972-2982.
- Kollnberger S. et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired ig-like receptors. J. Immunol. 2004; 173: 1699-1710.
- Kollnberger S. et al. Interaction of HLA-B27 homodimers with KiR3DL1 and KiR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur. J. Immunol. 2007; 37: 1313-1322.
- Chan A. T., Kollnberger S. D., Wedderburn L. R., Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KiR3DL2 in spondylarthritis. Arthr. and Rheum. 2005; 52: 3586-3595.
- Ben Dror L., Barnea E., Beer I. et al. The HLA-B*2705 peptidome. Arthr. and Rheum. 2010; 62: 420-429.
- López de Castro J. A. The HLA-B27 peptidome: building on the cornerstone. Arthr. and Rheum. 2010; 62: 316-319.
- Hülsmeyer M. et al. Dual, HLA-B27 subtypedependent conformation of a self-peptide. J. Exp. Med. 2004; 199: 27l-281.
- Baeten D., Kruithof E., Breban M., Tak P. P. Spondylarthritis in the absence of B lymphocytes. Arthr. and Rheum. 2008; 58: 730-733.
- Nocturne G. et al. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AiR) registry. Ann. Rheum. Dis. 2010; 69: 471- 472.
- Milia A. F. et al. Evidence for the prevention of enthesitis in HLA-B27/hbeta2m transgenic rats treated with a monoclonal antibody against TNFalpha J. Cell. Mol. Med. doi:10.1111/ j.1582-49342009.00984.x.
- May E. et al. CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J. Immunol. 2003; 170: 1099-1105.
- Taurog J. D. et al. Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8. Arthr. and Rheum. 2009; 60: 1977-1984.
- Dhaenens M. et al. Dendritic cells from spondylarthritis-prone HLA-B27-transgenic rats display altered cytoskeletal dynamics, class ii major histocompatibility complex expression, and viability. Arthr. and Rheum. 2009; 60: 2622-2632.
- Fert I. et al. Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B2/HUMAN beta2-microglobulin-transgenic rat lines. Arthr. and Rheum. 2008; 58: 3425-3429.
- Armaka M. et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 2008; 205: 331-337.
- Benjamin M., McGonagle D. Basic concepts of enthesis biology and immunology. J. Rheumatol. Suppl. 2009; 83: 12-13.
- Benjamin M. et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthr. and Rheum. 2007; 56: 224-233.
- Mathieu A. et al. The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmun. Rev. 2009; 8: 420-425.
- Rashid T., Ebringer A. Ankylosing spondylitis is linked to Klebsiella - the evidence. Clin. Rheumatol. 2007; 26: 858-864.
- Hannu T., Inman R., Granfors K., Leirisalo-Repo M. Reactive arthritis or post-infectious arthritis? Best Pract. Res. Clin. Rheumatol. 2006; 20: 419-433.
- Appel H. et al. Use of HLA-B27 tetramers to identify to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. Arthr. Res. Ther. 2004; 6: 521-534.
- Braun J. et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthr. and Rheum. 1995; 38: 499-505.
- Smolen J. S. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 2009; 68: 823-827.
- Lories R. J., Derese I., de Bari C., Luyten F. P. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthr. and Rheum. 2007; 56: 489- 497.
- Maksymowych W. P. Disease modification in ankylosing spondylitis. Nat. Rev. Rheumatol. 2010; 6: 75-81.
- Neidhart M. et al. Expression of cathepsin K and matrix metalloprooteinase 1 indicate persistent osteodestructive activity in longstanding ankylosing spondylitis. Ann. Rheum. Dis. 2009; 68: 1334-1339.
- Walsh N. C., Gravallese E. M. Bone remodeling in rheumatic disease: a question of balance. Immunol. Rev. 2010; 233: 301-312.
- Lories R. J., Luyten F. P., de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondylarthritis. Arthr. Res. Ther. 2009; 11: 221.
- Lories R. J., Luyten F. P. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev. 2005; 16: 287-298.
- Winkler D. G. et al. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J. Biol. Chem. 2004; 279: 36293-36298.
- van Bezooijen R. L. et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004; 199: 805-814.
- Schett G., Zwerina J., David J. P. The role of Wnt proteins in arthritis. Nat. Clin. Pract. Rheumatol. 2008; 4: 473-480.
- Diarra D., Stolina M., Polzer K. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 2007; l3: 156-163.
- Underhardt S., Diarra D., Katzenbeisser J. et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann. Rheum. Dis. 2010; 69: 592-597.
- Lories R. J., Derese I., Luyten F. P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J. Clin. Invest. 2005; 115: 1571-1579.
- Appel H. et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthr. and Rheum. 2009; 60: 3257-3262.
- Daoussis D. et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthr. and Rheum. 2010; 62: 150-158.